Tesaro Inc. (NASDAQ:TSRO) had its target price upped by analysts at Robert W. Baird to $120.00 in a research report issued to clients and investors on Monday. Robert W. Baird’s price target suggests a potential upside of 20.89% from the company’s previous close.

Several other research firms have also commented on TSRO. Royal Bank Of Canada upped their target price on Tesaro from $122.00 to $128.00 and gave the company an “outperform” rating in a research note on Monday. Wedbush boosted their price target on Tesaro from $107.00 to $139.00 and gave the company an “outperform” rating in a research report on Monday. FBR & Co boosted their price target on Tesaro from $102.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday. Bank of America Corp. raised Tesaro from a “neutral” rating to a “buy” rating in a research report on Monday. Finally, RBC Capital Markets boosted their price target on Tesaro to $128.00 in a research report on Monday. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $102.69.

Analyst Recommendations for Tesaro (NASDAQ:TSRO)

Shares of Tesaro (NASDAQ:TSRO) opened at 99.26 on Monday. The firm’s market cap is $5.10 billion. The firm has a 50-day moving average price of $96.42 and a 200-day moving average price of $68.96. Tesaro has a 52-week low of $29.51 and a 52-week high of $110.48.

Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.71) by $0.43. The firm earned $36.60 million during the quarter, compared to analyst estimates of $4.98 million. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. During the same period in the prior year, the firm posted ($1.51) earnings per share. Analysts predict that Tesaro will post ($7.36) EPS for the current fiscal year.

In other Tesaro news, VP Jeffrey H. Hanke sold 29,166 shares of the company’s stock in a transaction that occurred on Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the sale, the vice president now owns 29,166 shares in the company, valued at $2,509,442.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Martin H. Jr. Huber sold 408 shares of the company’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total value of $44,112.96. Following the sale, the senior vice president now owns 1,250 shares in the company, valued at approximately $135,150. The disclosure for this sale can be found here. 40.50% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. American International Group Inc. boosted its stake in shares of Tesaro by 3.0% in the second quarter. American International Group Inc. now owns 14,134 shares of the biopharmaceutical company’s stock valued at $1,188,000 after buying an additional 406 shares during the last quarter. Raymond James & Associates boosted its stake in shares of Tesaro by 4.7% in the second quarter. Raymond James & Associates now owns 11,062 shares of the biopharmaceutical company’s stock valued at $930,000 after buying an additional 500 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Tesaro by 3.5% in the second quarter. Metropolitan Life Insurance Co. NY now owns 19,006 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 637 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Tesaro by 23.9% in the second quarter. Teacher Retirement System of Texas now owns 3,954 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 762 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 834 shares during the last quarter. Hedge funds and other institutional investors own 88.81% of the company’s stock.

Tesaro Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.